Hugendubel.info - Die B2B Online-Buchhandlung 

Merkliste
Die Merkliste ist leer.
Bitte warten - die Druckansicht der Seite wird vorbereitet.
Der Druckdialog öffnet sich, sobald die Seite vollständig geladen wurde.
Sollte die Druckvorschau unvollständig sein, bitte schliessen und "Erneut drucken" wählen.

Combination Therapy In Dyslipidemia

BuchGebunden
205 Seiten
Englisch
Springererschienen am10.07.20152015
Comprising contributions from leading lipidologists from around the world, this book presents the latest and most comprehensive knowledge on the different options for combination therapy of dyslipidemia and includes discussion of future therapies that are currently in late stages of clinical evaluation.mehr
Verfügbare Formate
BuchKartoniert, Paperback
EUR96,29
BuchGebunden
EUR106,99
E-BookPDF1 - PDF WatermarkE-Book
EUR96,29

Produkt

KlappentextComprising contributions from leading lipidologists from around the world, this book presents the latest and most comprehensive knowledge on the different options for combination therapy of dyslipidemia and includes discussion of future therapies that are currently in late stages of clinical evaluation.
Zusammenfassung
Addresses a gap left by the latest dyslipidemia management guidelines

Current and comprehensive discussion of options for combination therapy of dyslipidemia

Contributions from an internationally acclaimed panel of expert lipidologists
Details
ISBN/GTIN978-3-319-20432-1
ProduktartBuch
EinbandartGebunden
Verlag
Erscheinungsjahr2015
Erscheinungsdatum10.07.2015
Auflage2015
Seiten205 Seiten
SpracheEnglisch
Gewicht469 g
IllustrationenVIII, 205 p. 22 illus., 15 illus. in color.
Artikel-Nr.15605894
Rubriken
GenreMedizin

Inhalt/Kritik

Inhaltsverzeichnis
â Foreword .- Statins and bile acid resins - is there a place for such a combination?.- Statins and fibrates - should it be recommended?.- Statins and ezetimibe - doubts or bright future?.- Statins and niacin - the end of residual risk therapy?.- Statins and omega-3 fatty acids - what more do we need?.- Statins and CETP inhibitors - anacetrapib and evacetrapib - the last hope?.- Statins and mipomersen - the issue of tolerability?.- Statins and lomitapide - a suitable response for HoFH.- Statins and PCSK9 inhibitors - defining the correct patients.- Other possible drug combination for dyslipidaemia.- Statins and nutraceuticals/functional food - Could be they combined?.- Lipid lowering therapy and apheresis - indications and outcomes.- Combination of lipid lowering agents with antihypertensive drugs - a joint fight against the two most important risk factors?.- Not only dyslipidaemia therapy - the time for polypills.- Drug Evaluation: Fenofibrate + simvastatin for the treatment of dyslipidemia: When and for whom?.- Drug Evaluation: Olmesartan medoxomil + rosuvastatin for the treatment of dyslipidemia and concomitant risk factors: A chance for better compliance?.- Conclusions and Take Home Message.mehr

Schlagworte